Loading...
•
Sep 30, 2024
Journey Medical Q3 2024 Earnings Report
Announced third quarter 2024 financial results with revenue of $14.6 million and highlighted the FDA approval of Emrosi™ for rosacea treatment.
Key Takeaways
Journey Medical reported solid third quarter 2024 results with total revenues of $14.6 million and highlighted the FDA approval of Emrosi™ for the treatment of inflammatory lesions of rosacea in adults, with launch expected in late Q1 or early Q2 of 2025.
U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults.
The launch of Emrosi is expected in late Q1 or early Q2 of 2025.
Total revenues for the third quarter ended September 30, 2024, were $14.6 million.
The company is completing manufacturing activities and deploying its sales force to enable patient access to Emrosi.
Forward Guidance
The company anticipates continued growth with the expected launch of Emrosi in late first quarter or early second quarter of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...